London, United Kingdom–(Newsfile Corp. – November 19, 2025) – Edison issues report on Tradedoubler (OMX: TRAD).
Tradedoubler has a strong proposition in performance marketing, with particular strengths in the partner (affiliate) and influencer areas. With the springboard of a leading position in Europe, it is now expanding operations into the US, the largest global advertising market. Its influencer marketing business, Metapic, is well-placed to take advantage of this dynamic and fast-growing market area. The group has a diverse customer base and a cash-positive balance sheet, giving credibility to its medium-term targets for 10% revenue growth and 25% EBITDA/gross profit margin, despite the well-publicised current travails of the marketing services industry. Not yet factored into our forecasts, a breakthrough in the US market could be transformational. In our view, the current rating overstates the risks and understates the opportunities.
Click here to read the full report.
All reports published by Edison are available to download free of charge from its website
www.edisongroup.com
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
enquiries@edisongroup.com
+44 (0)20 3077 5700
Connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275158
MIAMI, FLORIDA / ACCESS Newswire / December 7, 2025 / MSP Recovery, Inc. (NASDAQ:MSPR) (the…
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…